A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

Eslam, Mohammed and Newsome, Philip N and Anstee, Quentin M and Targher, Giovanni and Gomez, Manuel Romero and Zelber-Sagi, Shira and Wong, Vincent Wai-Sun and Dufour, Jean-François and Schattenberg, Jörn and Arrese, Marco and Valenti, Luca and Shiha, Gamal and Tiribelli, Claudio and Yki-Järvinen, Hannele and Fan, Jian-Gao and Gronbaek, Henning and Yilmaz, Yusuf and Cortez-Pinto, Helena and Oliveira, Claudia P and Bedossa, Pierre and Adams, Leon A and Zheng, Ming-Hua and Fouad, Yasser and Chan, Wah-Kheong and Mendez-Sanchez, Nahum and Ahn, Sang Hoon and Castera, Laurent and Bugianesi, Elisabetta and Ratziu, Vlad and George, Jacob (2020) A new definition for metabolic associated fatty liver disease: an international expert consensus statement. Journal of hepatology. ISSN 1600-0641. Available in full text to UHB Athens account holders via OpenAthens

Full text not available from this repository.
Official URL: https://www.journal-of-hepatology.eu/article/S0168...

Abstract

The exclusion of other chronic liver diseases including "excess" alcohol intake has till now been necessary to establish a diagnosis of metabolic-dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, "positive criteria" to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence of type 2 diabetes mellitus, or evidence of metabolic dysregulation. We propose that disease assessment and stratification of severity should extend beyond a simple dichotomous classification to steatohepatitis versus non-steatohepatitis. The group also suggests a set of criteria to define MAFLD associated cirrhosis and proposes a conceptual framework to consider other causes of fatty liver disease. Finally, we bring clarity to the distinction between diagnostic criteria and inclusion criteria for research studies and clinical trials. Reaching consensus on the criteria for MAFLD will help unify the terminology (e.g. for ICD-coding), enhance the legitimacy of clinical practice and clinical trials, improve clinical care and move the clinical and scientific field of liver research forward.

Item Type: Article
Additional Information: Available in full text to UHB Athens account holders via OpenAthens
Subjects: WI Digestive system. Gastroenterology
Divisions: Planned IP Care > Gastroentrology
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 17 Apr 2020 15:26
Last Modified: 17 Apr 2020 15:26
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2995

Actions (login required)

View Item View Item